3-Oxocholic Acid (Synonyms: 3-Dehydrocholic Acid) |
Catalog No.GC45339
One-Click Copy Product Info
|
3-Oxocholic Acid is a 3-oxo bile acid metabolite with bile acid metabolic activity.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2304-89-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
3-Oxocholic Acid is a 3-oxo bile acid metabolite with bile acid metabolic activity. 3-Oxocholic Acid regulates bile acid synthesis and transport-related genes and acts on FXR and TGR5 to maintain bile acid homeostasis. 3-Oxocholic Acid reduces Th17-mediated intestinal inflammation through regulation of immune pathways such as RORγt. 3-Oxocholic Acid can be used in studies of cholestasis, non-alcoholic steatohepatitis, and inflammatory bowel disease[1-4].
In vitro, 20µM 3-Oxocholic Acid was applied to mouse CD4+ T cells for 3 days. 3-Oxocholic Acid inhibited IL-17a production by the cells. 10µM 3-Oxocholic Acid was applied to HEK293 cells for 16 hours. 3-Oxocholic Acid decreased Gal4-DBD-RORγt reporter gene luciferase activity[5].
References:[1] Yan K, Chen W, Zhu H,et al. The Changes of Serum Metabolites in Diabetic GK Rats after Ileal Transposition Surgery. Obes Surg. 2019 Mar;29(3):882-890.
[2] Macdonald IA, Forrest TP, Costain GA, et al. Gut microbiota immaturity with DL-endopeptidase deficiency links antibiotic use to preterm late-onset sepsis. Cell Host Microbe. 2026 Apr 8;34(4):672-691.e13.
[3] Wahlström A, Sayin SI, Marschall HU, et al.Identification of 7alpha-, 12alpha-dihydroxy-3-oxo cholanoic acid as the major degradation product from cholic by C. perfringens. J Steroid Biochem. 1978 Apr;9(4):353-8.
[4] Takikawa H, Fernandez-Checa J C, Kuhlenkamp J, et al. Effect of indomethacin on the uptake, metabolism and excretion of 3-oxocholic acid: studies in isolated hepatocytes and perfused rat liver. Biochim Biophys Acta. 1991 Jun 24;1084(2):247-250.
[5] Hang S, Paik D, Yao L, et al. Bile acid metabolites control Th17 and Treg cell differentiation. Nature. 2019 Dec;576(7785):143-148.
| Cell experiment [1]: | |
|
Cell lines |
HEK293 cells (human embryonic kidney cell line) |
|
Preparation Method |
HEK293 cells were maintained in antibiotic-free Dulbecco's minimal essential medium (DMEM) containing 1% fetal calf serum (FCS) at 37°C, 5% CO2. HEK293 cells were transfected with a DNA mixture containing firefly luciferase reporter plasmid, Renilla luciferase plasmid, and Gal4-DNA binding domain-RORγ plasmid. 3-Oxocholic Acid (10μM) was added 24 hours after transfection. Luciferase activity was measured 16 hours after 3-Oxocholic Acid addition. |
|
Reaction Conditions |
10μM; 16h |
|
Applications |
3-Oxocholic Acid did not significantly reduce RORγt reporter activity in HEK293 cells. |
| References: [1] Hang S, Paik D, Yao L, et al. Bile acid metabolites control Th17 and Treg cell differentiation. Nature. 2019 Dec;576(7785):143-148. | |
| Cas No. | 2304-89-4 | SDF | |
| Synonyms | 3-Dehydrocholic Acid | ||
| Chemical Name | (5β,7α,12α)-7,12-dihydroxy-3-oxo-cholan-24-oic acid | ||
| Canonical SMILES | O=C1CC[C@@]2(C)[C@@](C[C@@H](O)[C@]3([H])[C@]2([H])C[C@H](O)[C@@]4(C)[C@@]3([H])CC[C@]4([H])[C@@H](CCC(O)=O)C)([H])C1 | ||
| Formula | C24H38O5 | M.Wt | 406.6 |
| Solubility | 30mg/mL in DMSO, 30mg/mL in DMF, 30mg/mL in Ethanol | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4594 mL | 12.2971 mL | 24.5942 mL |
| 5 mM | 491.9 μL | 2.4594 mL | 4.9188 mL |
| 10 mM | 245.9 μL | 1.2297 mL | 2.4594 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 18 reference(s) in Google Scholar.)